新华时评·民生无小事｜让集采药品真正成为人民健康的“守护盾”

Core Points - The recent 11th batch of national centralized drug procurement successfully awarded contracts for 55 drugs, contributing to a total of 490 quality and affordable essential and life-saving drugs entering the market over the past seven years [1] - The drug procurement policy aims to reduce prices through volume-based purchasing while ensuring drug quality remains a priority, emphasizing the need for stringent quality control throughout the procurement process [1][2] - New procurement rules require participating companies to have relevant production experience and compliance with quality management standards, ensuring that only qualified manufacturers can bid [1] Group 1 - The centralized drug procurement has successfully introduced 490 essential drugs into the market, benefiting public health [1] - The procurement process focuses on quality assurance, tightening controls on drug quality and ensuring that only established, low-risk drugs are included [1][2] - Strict quality thresholds have been established for bidding companies, requiring them to demonstrate production experience and compliance with regulatory standards [1] Group 2 - Continuous monitoring and regulation of selected drugs will be enforced, with penalties for companies that fail to maintain quality standards post-selection [2] - The emphasis on quality control throughout the drug lifecycle is crucial for ensuring public trust and safety in the procurement process [2] - A dual approach of strict process management and dynamic monitoring is necessary to uphold drug quality and realize the benefits of the procurement policy [2]